 As secondary objectives, baseline TLR-9 intracellular staining of B-CLL cells, and in vitro assays to assess the potential of B-CLL cells to undergo apoptosis in conjunction with GNKG168 therapy will be examined. Baseline characteristics of B-CLL will be examined including interphase genetics, FISH CLL, IgVH mutational status, expression of ZAP70, β2-microglobulin and the expression of the prognostic marker CD38 in peripheral blood cells at baseline and during treatment and baseline immune SNPs FcγRIIIa, FcγRIIa, TNF-α, IFN-γ, CD40 and others. As pharmacodynamics parameters, the expression of B-cell and T-cell activation markers including IL-21 receptor upregulation, NK cell markers, and cytokines will be investigated. 